Psychedelic-Assisted Therapies

Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:CYBN) announced that the Food and Drug Administration has granted Breakthrough Therapy designation to CYB003, its proprietary deuterated psilocybin analog targeting the adjunctive treatment of Major Depressive Disorder (MDD.)  The...

Psyence Biomedical Ltd (NASDAQ:PBM) recently announced that its wholly-owned subsidiary, Psyence Australia (Pty) received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. The study will examine the use of...

Shortly following the news on FDA's "breakthrough therapy" designation and the 12-week clinical durability data on its LSD therapy for generalized anxiety, psychedelics biotech MindMed (NASDAQ:MNMD) announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per...

Mind Medicine (MindMed) (NASDAQ:MNMD) announced that the FDA has granted the "breakthrough therapy" designation to its MM120 (lysergide d-tartrate) program for the treatment of Generalized Anxiety Disorder (GAD).  The clinical-stage psychedelics biotech firm will now join industry counterparts...

Discussion surrounding science, industry and psychedelics reform is experiencing an all-time high, and 2024 promises to not only continue but further this trend.  In 2023, the psychedelics market saw transformative expansion driven by favorable trial outcomes, attracting significant investments...

State-level psychedelics policy reform is moving fast throughout the U.S. Below is a recap of February 2024 moves. Connecticut: Democrat-led HB5297 would decriminalize possession of less than 1.5 ounces of psilocybin. Formerly a class A misdemeanor, the first offense would now imply a $150 fine,...

Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items concerning the last two weeks of February 2024. See previous edition Psychedelics Headlines: Trauma-Informed Care, Valentine’s Day & MDMA, Academics On Drugs Research Validation of the...

Nasdaq-listed, GH Research (NASDAQ:GHRS) is a clinical-stage biopharma business developing novel 5-MeO-DMT therapies as transformative treatment of psychiatric and neurological disorders. Its reported yearly financial results show: Cash position of $ 222.7 million by December 31, 2023, an 11.5%...

Compass Pathways (NASDAQ:CMPS), one of the key players in the psychedelics biotech space, reported its financial results for the fourth quarter of 2023. Numbers: Cash and cash equivalents were $220.2 million by December 31, 2023, up over 50% as compared to the amount held by December 31, 2022 ($...

Welcome to a new episode of our Benzinga Psychedelics Podcast, this time joined by business trendspotter and "psychedelics concierge" Zappy Zapolin. He has served in a range of positions, from advisor to psychedelic companies like KetaMD – acquired by Braxia Scientific (OTC:BRAXF) and chief...

The medical psychedelics field stands at a pivotal juncture. With MDMA-assisted therapy close to federal legalization for the treatment of PTSD in the U.S. and other psychedelic substances potentially following suit, these therapies are poised to revolutionize treatment for certain mental health...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) announced its financial results for the year ended December 31, 2023 along with a business update. Numbers: Cash and cash equivalents totaled $99.7 million by Dec. 31, 2023, an almost 30% reduction compared to the $142.1 million held by December 31, 2022...

Australian biopharma company MindBio Therapeutics Corp. has shared positive topline results from its completed take-home microdosing clinical trial on major depressive disorder.  The treatment provided to the 20 participants is MB22001, the company's microdose formulation of a self-titratable...

Welcome to Benzinga's psychedelics headlines roundup. This is our pick of must-read news items concerning the last few days of January and the first two weeks of February 2024. See previous edition: Anti-inflammatory Effects, Global Drug Survey, ‘Synthetic Surprise,’ UK’s Harm...

While federal reform on psychedelic substances advances and FDA approval of MDMA-assisted therapy for the treatment of Post Traumatic Stress Disorder seems imminent, local resolutions are moving at a faster pace in certain states like Michigan or Massachusetts, where an eighth city recently adopted...